Xeris Biopharma (XERS) Scheduled to Post Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS - Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Xeris Biopharma to post earnings of ($0.12) per share for the quarter. Xeris Biopharma has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Wednesday, March 6th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $44.39 million for the quarter, compared to analysts' expectations of $45.50 million. Xeris Biopharma had a negative return on equity of 610.76% and a negative net margin of 37.98%. During the same period last year, the business earned ($0.10) EPS. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Trading Up 1.6 %

XERS stock traded up $0.03 during mid-day trading on Friday, hitting $1.89. 1,130,197 shares of the company were exchanged, compared to its average volume of 2,054,828. The company has a quick ratio of 1.23, a current ratio of 1.64 and a debt-to-equity ratio of 49.27. The firm has a market capitalization of $280.19 million, a P/E ratio of -4.13 and a beta of 2.37. The business has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $2.20. Xeris Biopharma has a 12-month low of $1.46 and a 12-month high of $3.26.

Analyst Ratings Changes

XERS has been the topic of several research reports. HC Wainwright increased their price target on shares of Xeris Biopharma from $5.50 to $6.00 and gave the stock a "buy" rating in a research report on Thursday, March 7th. Oppenheimer initiated coverage on shares of Xeris Biopharma in a research report on Thursday, March 28th. They set an "outperform" rating and a $5.00 price target on the stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.